MD4231C1 - Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis - Google Patents
Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis Download PDFInfo
- Publication number
- MD4231C1 MD4231C1 MDA20120102A MD20120102A MD4231C1 MD 4231 C1 MD4231 C1 MD 4231C1 MD A20120102 A MDA20120102 A MD A20120102A MD 20120102 A MD20120102 A MD 20120102A MD 4231 C1 MD4231 C1 MD 4231C1
- Authority
- MD
- Moldova
- Prior art keywords
- portal
- treatment
- gastropathies
- carbazochrome
- troxerutin
- Prior art date
Links
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 13
- 208000012895 Gastric disease Diseases 0.000 title claims abstract description 12
- XSXCZNVKFKNLPR-SDQBBNPISA-N carbazochrome Chemical compound NC(=O)N/N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 XSXCZNVKFKNLPR-SDQBBNPISA-N 0.000 title claims abstract description 8
- 229960002631 carbazochrome Drugs 0.000 title claims abstract description 8
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 title claims abstract description 8
- 229960003232 troxerutin Drugs 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 title abstract description 5
- 238000002360 preparation method Methods 0.000 description 8
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 208000018556 stomach disease Diseases 0.000 description 5
- 230000003902 lesion Effects 0.000 description 4
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 201000002282 venous insufficiency Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010056091 Varices oesophageal Diseases 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000024170 esophageal varices Diseases 0.000 description 2
- 201000010120 esophageal varix Diseases 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000027185 varicose disease Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010057267 Periphlebitis Diseases 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 208000014306 Trophic disease Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 201000002816 chronic venous insufficiency Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Invenţia se referă la medicină, în special la hepatologie şi poate fi utilizată pentru tratamentul gastropatiilor portale în ciroza hepatică. The invention relates to medicine, especially to hepatology and can be used for the treatment of portal gastropathies in liver cirrhosis.
Este cunoscută utilizarea preparatelor antiulceroase, şi anume H2 antihistaminice şi a preparatelor de blocare a pompei protonice pentru tratamentul gastropatiilor portale la pacienţii cu ciroză hepatică, care se administrează per os: Famotidin, câte 20…40 mg, de 2 ori pe zi, Omeprazol, câte 20 mg/zi, timp de 2…3 săptămâni [1]. It is known to use antiulcer preparations, namely H2 antihistamines and proton pump blocking preparations for the treatment of portal gastropathy in patients with liver cirrhosis, which are administered orally: Famotidine, 20...40 mg each, 2 times a day, Omeprazole, 20 mg/day each, for 2...3 weeks [1].
Dezavantajele preparatelor menţionate constau în scăderea acidităţii gastrice, apariţia refluxului gastro-esofagian, care poate contribui la declanşarea ulterioară a hemoragiilor din varicele esofagiene, la utilizarea lor îndelungată sau repetată pot afecta funcţia hepatică, ceea ce poate duce la progresarea cirozei hepatice. The disadvantages of the mentioned preparations consist in the decrease of gastric acidity, the occurrence of gastro-oesophageal reflux, which can contribute to the subsequent triggering of haemorrhages from esophageal varices, their long or repeated use can affect liver function, which can lead to the progression of liver cirrhosis.
Problema pe care o rezolvă invenţia propusă constă în utilizarea unui preparat, care să îmbunătăţească trofica mucoasei esofagului şi stomacului, să micşoreze permeabilitatea, să amelioreze microcirculaţia mucoasei, contribuind astfel la regenerarea leziunilor mucoasei şi, respectiv, la micşorarea stazei venoase microcirculatorii şi a hipoxiei tisulare locale. The problem that the proposed invention solves consists in the use of a preparation that improves the trophicity of the mucosa of the esophagus and stomach, reduces permeability, improves the microcirculation of the mucosa, thus contributing to the regeneration of mucosal lesions and, respectively, to the reduction of microcirculatory venous stasis and tissue hypoxia local.
Esenţa invenţiei constă în aceea că se utilizează un remediu medicamentos pe bază de troxerutin şi carbazocrom, în doză de 300 mg şi, respectiv, 3 mg, pentru tratamentul gastropatiilor portale în ciroza hepatică. Totodată, remediul medicamentos se administrează câte 1 comprimat, de 2…3 ori pe zi, per os, timp de 14…30 zile. The essence of the invention is that a medicinal remedy based on troxerutin and carbazochrome is used, in a dose of 300 mg and 3 mg, respectively, for the treatment of portal gastropathies in liver cirrhosis. At the same time, the medicinal remedy is administered 1 tablet, 2...3 times a day, per bone, for 14...30 days.
Rezultatul invenţiei constă în utilizarea unui preparat medicamentos pentru tratamentul gastropatiilor portale la pacienţii cu ciroză hepatică, care este bine tolerat de pacienţi, nu provoacă efecte adverse şi nu necesită spitalizare. The result of the invention consists in the use of a medicinal preparation for the treatment of portal gastropathy in patients with liver cirrhosis, which is well tolerated by patients, does not cause adverse effects and does not require hospitalization.
Avantajele utilizării remediului medicamentos pe bază de troxerutin şi carbazocrom, în doză de 300 mg şi, respectiv, 3 mg conform invenţiei sunt: The advantages of using the medicinal remedy based on troxerutin and carbazochrome, in doses of 300 mg and 3 mg, respectively, according to the invention are:
- este bine tolerat de pacienţi; - it is well tolerated by patients;
- nu provoacă complicaţii specifice preparatelor antiulceroase; - does not cause complications specific to antiulcer preparations;
- poate fi administrat timp îndelungat şi fără reacţii adverse; - it can be administered for a long time and without adverse reactions;
- ameliorează microcirculaţia şi trofica mucoasei gastrice; - improves microcirculation and trophicity of the gastric mucosa;
- stimulează regenerarea mucoasei gastrice. - stimulates the regeneration of the gastric mucosa.
Pentru tratamentul gastropatiilor portale la pacienţii cu ciroză hepatică în scopul ameliorării microcirculaţiei, reducerii permeabilităţii capilarelor, creşterii tonusului şi a elasticităţii venelor din sistemul venei porte, inclusiv a varicelor esofagiene şi gastrice, şi stimulării regenerării mucoasei gastrice se indică toxivenol, care conţine troxerutin 300 mg şi carbazocrom 3 mg într-un comprimat, care se administrează câte 1 comprimat, de 2…3 ori pe zi, per os, timp de 14…30 zile. Toxivenol, which contains troxerutin 300 mg, is indicated for the treatment of portal gastropathy in patients with liver cirrhosis in order to improve microcirculation, reduce capillary permeability, increase the tone and elasticity of the veins in the portal vein system, including esophageal and gastric varices, and stimulate the regeneration of the gastric mucosa and carbazochrome 3 mg in one tablet, which is administered 1 tablet, 2...3 times a day, orally, for 14...30 days.
Este cunoscută utilizarea remediului medicamentos pe bază de troxerutin şi carbazocrom, în doză de 300 mg şi, respectiv, 3 mg într-un comprimat, în insuficienţa venoasă cronică a membrelor inferioare cu senzaţie de greutate în picioare, boala varicoasă, tromboflebita venelor subcutanate, periflebită, edem posttraumatic, hematoame, afecţiuni trofice, tratamentul simptomatic al acutizării hemoroizilor, fragilitate mărită a capilarelor. Preparatul Toxivenol a fost utilizat pentru tratarea gastropatiilor portale, şi anume a leziunilor eroziv-ulceroase gastrice la 23 pacienţi cu ciroză hepatică şi hipertensiune portală cu efect clinic favorabil şi confirmare endoscopică de regenerare a leziunilor în medie peste 14…28 zile, fiind de o eficacitate majoră, cu ameliorarea mai rapidă a indicilor clinici şi paraclinici şi a duratei de remisie a bolii. Acest preparat are un efect protector asupra peretelui varicelor, ce micşorează riscul accidentului hemoragic. It is known to use the medicinal remedy based on troxerutin and carbazochrome, in a dose of 300 mg and 3 mg in one tablet, respectively, in chronic venous insufficiency of the lower limbs with a feeling of heaviness in the legs, varicose disease, thrombophlebitis of subcutaneous veins, periphlebitis , posttraumatic edema, hematomas, trophic disorders, symptomatic treatment of hemorrhoids exacerbation, increased capillary fragility. The preparation Toxivenol was used for the treatment of portal gastropathies, namely gastric erosive-ulcerative lesions in 23 patients with liver cirrhosis and portal hypertension with a favorable clinical effect and endoscopic confirmation of regeneration of the lesions on average over 14...28 days, being of an effectiveness major, with faster improvement of clinical and paraclinical indices and duration of disease remission. This preparation has a protective effect on the wall of varicose veins, which reduces the risk of hemorrhagic accident.
Exemplu Example
Pacientul S., 53 ani, a fost internat în secţia chirurgie în stare gravă cu diagnosticul de ciroză hepatică HBV subcompensată, stare după hemoragie din varice esofagiene stopată endoscopic, gastropatie portală eroziv-ulceroasă gr. III-IV, risc iminent de hemoragie gastrică. La examenul endoscopic s-au constatat multiple leziuni acute eroziv-ulceroase ale regiunii subcardiace a stomacului acoperite cu hemosiderină, stază venoasă gastrică. Patient S., 53 years old, was hospitalized in the surgery department in serious condition with the diagnosis of undercompensated HBV liver cirrhosis, condition after bleeding from esophageal varices stopped endoscopically, portal erosive-ulcerative gastropathy gr. III-IV, imminent risk of gastric hemorrhage. The endoscopic examination revealed multiple acute erosive-ulcerative lesions of the subcardiac region of the stomach covered with hemosiderin, gastric venous stasis.
S-a administrat remediul medicamentos pe bază de troxerutin şi carbazocrom, în doză de 300 mg şi, respectiv, 3 mg într-un comprimat, pentru tratamentul gastropatiilor portale în ciroza hepatică, care se administrează câte 1 comprimat, de 3 ori pe zi, per os, timp de 28 zile. The medicinal remedy based on troxerutin and carbazochrome was administered, in a dose of 300 mg and 3 mg in one tablet, respectively, for the treatment of portal gastropathy in liver cirrhosis, which is administered 1 tablet each, 3 times a day, per os , for 28 days.
După 9 zile de tratament starea pacientului s-a ameliorat, au dispărut durerile şi disconfortul epigastric. La examenul endoscopic de control s-a constatat epitelizarea leziunilor ulceroase, micşorarea dimensiunilor, a numărului de eroziuni şi a stazei mucoasei gastrice. After 9 days of treatment, the patient's condition improved, the epigastric pain and discomfort disappeared. During the control endoscopic examination, the epithelialization of the ulcerous lesions, the decrease in size, the number of erosions and the stasis of the gastric mucosa were found.
Tratamentul cu toxivenol a fost continuat, la examenele endoscopice repetate peste 14 şi 28 zile s-a stabilit regenerarea completă a mucoasei gastrice. The treatment with toxivenol was continued, at repeated endoscopic examinations over 14 and 28 days, complete regeneration of the gastric mucosa was established.
1. Шерлок Ш., Дули Д. Заболевания печени и желчнных путей. Москва, 1999, с. 859 1. Sherlock Sh., Duli D. Diseases of the liver and bile ducts. Moscow, 1999, p. 859
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20120102A MD4231C1 (en) | 2012-11-08 | 2012-11-08 | Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20120102A MD4231C1 (en) | 2012-11-08 | 2012-11-08 | Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD4231B1 MD4231B1 (en) | 2013-06-30 |
| MD4231C1 true MD4231C1 (en) | 2014-01-31 |
Family
ID=48749682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20120102A MD4231C1 (en) | 2012-11-08 | 2012-11-08 | Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD4231C1 (en) |
Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985003864A1 (en) * | 1984-03-01 | 1985-09-12 | Casley Smith John Royle | Treatment of high protein oedemas by direct application of benzo-pyrones |
| CH671021A5 (en) * | 1987-05-07 | 1989-07-31 | Espanola Prod Quimicos | Prodn. of hydroxy:ethylated diosmin mixts. - useful for treating intoxication |
| FR2661610A1 (en) * | 1990-05-02 | 1991-11-08 | Rhone Poulenc Sante | Novel lyophilised form of diosmin and its preparation |
| FR2668705A1 (en) * | 1990-11-06 | 1992-05-07 | Bouchara Sa | Novel skin preparations having a phlebotonic action and process for preparing them |
| EP0541874A1 (en) * | 1990-05-11 | 1993-05-19 | Jérôme CORBIERE | Compositions containing diosmin |
| FR2692145A1 (en) * | 1992-06-10 | 1993-12-17 | Bellon Labor Sa Roger | Topical compsns. having a vascular protecting and veinotonic action - contain diosmin, fatty acid(s), hydrating agent, neutralising agent, gelling agent and opt. stabilisers, preservatives, colours, perfumes, etc. |
| JPH08301757A (en) * | 1995-05-10 | 1996-11-19 | Kureha Chem Ind Co Ltd | Hsp47 synthesis suppressing agent |
| NZ280418A (en) * | 1994-11-08 | 1997-03-24 | Adir | Diosmin composition; effervescent granule, in tablet or sachet form containing micronised diosmin |
| CA2287363A1 (en) * | 1997-05-13 | 1998-11-19 | Remacle, Jose | Use of a pharmaceutical composition for treating and/or preventing ischemia |
| DE19922287A1 (en) * | 1998-05-15 | 1999-11-25 | Coletica Lyon | Cosmetic, dermatological, pharmaceutical, dietetic or food compositions, e.g. for improving skin condition, comprise flavonoid esters |
| JP2000023635A (en) * | 1998-07-10 | 2000-01-25 | M P G Kk | Granule nutrient auxiliary food |
| WO2000015237A1 (en) * | 1998-09-15 | 2000-03-23 | Korea Research Institute Of Bioscience And Biotechnology | Composition containing rutin and quercetin for preventing or treating elevated blood lipid level-related diseases |
| KR20000019719A (en) * | 1998-09-15 | 2000-04-15 | 박호군 | Composition comprising diosmin for preventing and treating hyperlipidemia and arteriosclerosis |
| KR20010007624A (en) * | 2000-10-06 | 2001-01-26 | 박호군 | Composition for preventing and treating atherosclerosis, hyperlipidemia, hepatic diseases and glycosemia, comprising neohesperidin dihydrochalcone |
| KR20010007625A (en) * | 2000-10-06 | 2001-01-26 | 박호군 | Composition for preventing and treating atherosclerosis and hyperlipidemia, comprising diosmin |
| WO2002020030A2 (en) * | 2000-09-11 | 2002-03-14 | Michael D Stander | Use of buchu extracts for hypertension |
| WO2004032942A1 (en) * | 2002-10-11 | 2004-04-22 | Laboratoires Innothera Sas | Dry oral phlebotonic and vasculoprotective formulation for the treatment of venous insufficiency, capillary fragility and haemorrhoids, in the pharmaceutical form of a chewable tablet containing diosmin |
| FR2857665A1 (en) * | 2003-07-16 | 2005-01-21 | Centre Nat Rech Scient | New 3-halo flavone derivatives useful for treating disorders involving an excess of oxidizing species, e.g. cancer, ischemic diseases, dermatosis, neurodegenerative diseases, inflammatory diseases |
| US20060040911A1 (en) * | 2003-01-06 | 2006-02-23 | Liao Benedict S | Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus) |
| CN1823807A (en) * | 2006-01-11 | 2006-08-30 | 刘展欣 | Micronize diosmin and hesperidine composition suppository |
| EP1707192A2 (en) * | 2005-03-30 | 2006-10-04 | Therapicon Srl | Pharmaceutical composition |
| MX2007011002A (en) * | 2007-09-07 | 2009-03-09 | World Trade Imp Export Wtie Ag | Pharmaceutical composition combining various venotonic and vasoprotective agents for the treatment of chronic venous insufficiency. |
-
2012
- 2012-11-08 MD MDA20120102A patent/MD4231C1/en not_active IP Right Cessation
Patent Citations (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985003864A1 (en) * | 1984-03-01 | 1985-09-12 | Casley Smith John Royle | Treatment of high protein oedemas by direct application of benzo-pyrones |
| CH671021A5 (en) * | 1987-05-07 | 1989-07-31 | Espanola Prod Quimicos | Prodn. of hydroxy:ethylated diosmin mixts. - useful for treating intoxication |
| FR2661610A1 (en) * | 1990-05-02 | 1991-11-08 | Rhone Poulenc Sante | Novel lyophilised form of diosmin and its preparation |
| EP0541874A1 (en) * | 1990-05-11 | 1993-05-19 | Jérôme CORBIERE | Compositions containing diosmin |
| FR2668705A1 (en) * | 1990-11-06 | 1992-05-07 | Bouchara Sa | Novel skin preparations having a phlebotonic action and process for preparing them |
| FR2692145A1 (en) * | 1992-06-10 | 1993-12-17 | Bellon Labor Sa Roger | Topical compsns. having a vascular protecting and veinotonic action - contain diosmin, fatty acid(s), hydrating agent, neutralising agent, gelling agent and opt. stabilisers, preservatives, colours, perfumes, etc. |
| FR2692145B1 (en) * | 1992-06-10 | 1995-05-05 | Bellon Labor Sa Roger | New composition for topical use containing diosmin. |
| NZ280418A (en) * | 1994-11-08 | 1997-03-24 | Adir | Diosmin composition; effervescent granule, in tablet or sachet form containing micronised diosmin |
| JPH08301757A (en) * | 1995-05-10 | 1996-11-19 | Kureha Chem Ind Co Ltd | Hsp47 synthesis suppressing agent |
| CA2287363A1 (en) * | 1997-05-13 | 1998-11-19 | Remacle, Jose | Use of a pharmaceutical composition for treating and/or preventing ischemia |
| DE19922287A1 (en) * | 1998-05-15 | 1999-11-25 | Coletica Lyon | Cosmetic, dermatological, pharmaceutical, dietetic or food compositions, e.g. for improving skin condition, comprise flavonoid esters |
| JP2000023635A (en) * | 1998-07-10 | 2000-01-25 | M P G Kk | Granule nutrient auxiliary food |
| WO2000015237A1 (en) * | 1998-09-15 | 2000-03-23 | Korea Research Institute Of Bioscience And Biotechnology | Composition containing rutin and quercetin for preventing or treating elevated blood lipid level-related diseases |
| KR20000019719A (en) * | 1998-09-15 | 2000-04-15 | 박호군 | Composition comprising diosmin for preventing and treating hyperlipidemia and arteriosclerosis |
| WO2002020030A2 (en) * | 2000-09-11 | 2002-03-14 | Michael D Stander | Use of buchu extracts for hypertension |
| KR20010007624A (en) * | 2000-10-06 | 2001-01-26 | 박호군 | Composition for preventing and treating atherosclerosis, hyperlipidemia, hepatic diseases and glycosemia, comprising neohesperidin dihydrochalcone |
| KR20010007625A (en) * | 2000-10-06 | 2001-01-26 | 박호군 | Composition for preventing and treating atherosclerosis and hyperlipidemia, comprising diosmin |
| WO2004032942A1 (en) * | 2002-10-11 | 2004-04-22 | Laboratoires Innothera Sas | Dry oral phlebotonic and vasculoprotective formulation for the treatment of venous insufficiency, capillary fragility and haemorrhoids, in the pharmaceutical form of a chewable tablet containing diosmin |
| US20060040911A1 (en) * | 2003-01-06 | 2006-02-23 | Liao Benedict S | Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus) |
| FR2857665A1 (en) * | 2003-07-16 | 2005-01-21 | Centre Nat Rech Scient | New 3-halo flavone derivatives useful for treating disorders involving an excess of oxidizing species, e.g. cancer, ischemic diseases, dermatosis, neurodegenerative diseases, inflammatory diseases |
| EP1707192A2 (en) * | 2005-03-30 | 2006-10-04 | Therapicon Srl | Pharmaceutical composition |
| CN1823807A (en) * | 2006-01-11 | 2006-08-30 | 刘展欣 | Micronize diosmin and hesperidine composition suppository |
| MX2007011002A (en) * | 2007-09-07 | 2009-03-09 | World Trade Imp Export Wtie Ag | Pharmaceutical composition combining various venotonic and vasoprotective agents for the treatment of chronic venous insufficiency. |
Non-Patent Citations (1)
| Title |
|---|
| Шерлок Ш., Дули Д. Заболевания печени и желчнных путей. Москва, 1999, с. 859 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD4231B1 (en) | 2013-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Prichard | Hypotensive action of pronethalol | |
| KR20070007887A (en) | Use of Treprostinil to Treat Neuropathic Diabetic Foot Ulcers | |
| JP2007514750A5 (en) | ||
| JP2011057709A5 (en) | ||
| CN102917719A (en) | Kit of medicines for treating and/or preventing skin ulcers | |
| MD4231C1 (en) | Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis | |
| Som et al. | New approach to the treatment of esophageal varices | |
| Döhler et al. | Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage | |
| MD4316C1 (en) | Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating portal gastropathies in patients with liver cirrhosis | |
| CN101172150A (en) | Externally used medicament for treating beriberi | |
| Kamiike et al. | Simultaneous surgery for coronary artery disease and gastric cancer | |
| BR112015027051A2 (en) | USE OF LANDIOLOL HYDROCHLORIDE IN THE LONG-TERM TREATMENT OF TACHYARRHYTHMIAS | |
| CN103340863A (en) | Application of nicotinamide to preparation of drugs for healing diabetic wounds | |
| CN112656938B (en) | Application of ginsenoside Re and lysozyme in preparation of medicine for treating or preventing abdominal aortic aneurysm | |
| MD4232C1 (en) | Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure | |
| CN116510023A (en) | Application of chemical in preparation of product for preventing and/or treating chronic wound | |
| RO134539A0 (en) | Semisolid pharmaceutical preparation for combined topical therapy of anorectal pathology | |
| Bancroft et al. | The treatment of actinomycosis with thymol | |
| Mohanty et al. | A randomised controlled study on efficacy of propranolol, prednisolone and propranolol with prednisolone in infantile hemangioma | |
| MD4317C1 (en) | Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure | |
| Reddy et al. | Bilateral nipple necrosis after intravenous vasopressin therapy | |
| CN208864399U (en) | Tourniquet is used in a kind of dialysis | |
| RU2364397C1 (en) | Chemotherapy mode in hepatic metastases of gastric carcinoma | |
| RU2654778C2 (en) | Method for reducing pressure in varix in portal hypertension during endoligation under anaesthesia | |
| Qadri et al. | Progress in the Treatment of Infantile Hemangioma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) |